Schedule an introductory call today!

+31 (0) 629075858

RegPak BioPharma Consulting

RegPak BioPharma Consulting (RegPak) is a full-service consulting company based in The Netherlands and Romania. RegPak offers a consultancy that adapts to new demands, business pressures with understanding of clients’ current and future needs.

RegPak high quality consultancy services include a Strategic Planning offering that assists clients to develop new products, speed regulatory approval and reduce time to market. 

RegPak applies its expertise in practical and logical ways to help companies worldwide, continually striving for excellence and sharing its principles and practices through training, presentations and publications. It develops services and creative offerings that provide new and more efficient ways for clients, their vendors, suppliers, and service providers to conduct their businesses within regulatory compliance and with reduced risk. 

RegPak approach is interdisciplinary, with a strong emphasis on the science underlying the product. It also prioritizes client confidentiality and assured security of data. As an independent organization, RegPak avoids all conflicts of interest.

The service leverages RegPak’s expertise
in many therapeutic areas:

oncology

autoimmune diseases

cardiovascular

CNS

dermatology

infectious diseases

It includes all the key expertise and processes required to satisfy regulatory requirements and smooth the way to market approval for biologicals (including biosimilars), vaccines, small molecules, generics, cosmeceuticals, nutraceutical/herbal products and medical devices. RegPak’s Expertise:

  • Regulatory intelligence & expert knowledge of global regulatory requirements
  • Clinical Trial Monitoring Support for BioPharma& Medical Device Companies
  • Pharmacovigilance
  • Product Promotion & Labelling
  • QA & Inspections
  • Due Diligence
  • Pricing and Reimbursement
  • Technical Writing

Contact us

Aristotelesstraat 16, 1064 LD, Amsterdam

RO Address: Bulevardul Unirii 11, Bloc 2B, Sector 4, Bucharest

Tele-Fax : +31 (0) 207729539

Phone: +31 6290 75858


Email: info@regpakbiopharma.com

bd@regpakbiopharma.com

Website: regpakbiopharma.com

LEARN MORE

Go to article: Home | Antibiotic AdjacentGo to article: In this issueGo to article: ContentsGo to article: SHL Company InsightGo to article: SHL MedicalGo to article: TiveGo to article: Controlant Company InsightGo to article: ControlantGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: L.B. Bohle MaschinenGo to article: L.B Bohle Company InsightGo to article: ACG WorldwideGo to article: CommentGo to article: HPV infections drop due to widespread vaccinationGo to article: Europe reports the highest prevalence of chronic cough across the 7MMGo to article: How could vaccine hesitancy affect the prevalence of hearing disorders?Go to article: Datwyler Company Insight Go to article: DatwylerGo to article: RegPakGo to article: PfeifferGo to article: In DepthGo to article: Antibiotic adjacent: the alternatives tackling AMR Go to article: Regenerative medicine: ready for the big leagues? Go to article: Human challenge trials: pandemic exit strategy or ethical nightmare?Go to article: Drug dispensing goes digitalGo to article: Could this Novartis initiative finally cure sickle cell disease?Go to article: Centessa Pharmaceuticals: forging a new path for pharma R&DGo to article: Biomax Company InsightGo to article: BiomaxGo to article: DuojectGo to article: Duoject Company InsightGo to article: In DataGo to article: Deals analysisGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article: Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: The Solubility Company - Company Insight Go to article: The Solubility companyGo to article: MyonexGo to article: BaxterGo to article: EventsGo to article: Next issue